약어 HCV, hepatitis C virus DAA, direct acting antiviral SOF, sofosbuvir LDV, ledipasvir DCV, daclatasvir ASV, asunaprevir OPr-D, ombitasvir/paritaprevir/ritonavir plus dasabuvir EBR/GZR, elbasvir/grazoprevir G/P, glecaprevir/pibrentasvir VEL, velpatasvir VOX, voxilaprevir O, no clinical significant interaction expected △, potential interaction which may require a dose adjustment, altered timing o..
